Q BioMed News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.07.22	Q BioMed Inc. Provides Update to Shareholders (PR Newswire)
08.11.21	Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership (PR Newswire)
24.08.21	Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical Testing (PR Newswire)
10.08.21	Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada (PR Newswire)
12.07.21	Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East (PR Newswire)
07.01.21	Strontium89 Now Reimbursed in Hospital and Outpatient Settings for Metastatic Bone Pain Treatment (PR Newswire)
29.12.20	Q BioMed Updates Shareholders at Year End (PR Newswire)
11.08.20	Q BioMed gibt bekannt, dass Strontium89 ab September 2020 in der EU und in der übrigen Welt über das benannte Patientenprogramm zur Schmerzlinderung bei Knochenmetastasen verfügbar sein wird (PR Newswire)
11.08.20	Q BioMed annonce que le Strontium89 sera disponible à partir de septembre 2020 dans le cadre d'un programme de patients désignés pour le traitement de la douleur des métastases osseuses dans l'Uni... (PR Newswire)
11.08.20	Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World (PR Newswire)
11.08.20	Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World (PR Newswire)
22.07.20	Q Biomed to Scale up Production of Uttroside-B, a Novel Chemotherapeutic for Liver Cancer, in Preparation for IND Filing (PR Newswire)
08.07.20	Q BioMed Announces Global Distribution Partnership With Caligor Coghlan Pharma Services for its Non-Opioid Cancer Palliation Drug (PR Newswire)
07.04.20	Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a Minimum of $3,800,000 of Debt Conversion (PR Newswire)
31.03.20	Q BioMed Adds to Leadership Team With Global Head of Regulatory Affairs (PR Newswire)
30.03.20	Q BioMed Expands Leadership Team With Chief Commercial Officer (PR Newswire)
12.03.20	Q BioMed Treats its First Patient in Commercial Setting Following Product Launch (PR Newswire)
07.01.20	Q BioMed Provides a Shareholder Update Ahead of the Commercial Launch of its First Drug (PR Newswire)
05.11.19	Q BioMed Announces $7.5M Grant Benefiting its Preclinical Product Development Pipeline (PR Newswire)
03.10.19	Q BioMed Announces Commercial Partnership With Jubilant Radiopharma for the Distribution of its Non-Opioid Cancer Palliation Drug in the United States (PR Newswire)
02.10.19	Q BioMed Announces Legal Settlement and Acquisition of FDA Approved Non-Opioid Metastatic Cancer Pain Drug (PR Newswire)
25.01.19	Q BioMed Technology Partner Mannin Research Enters Into Collaboration With McMaster University for Glaucoma Drug Candidate MAN-01 (PR Newswire)
16.01.19	Q BioMed Adds Clinical Psychologist at Yale's Child Study Center, Dr. Pamela Ventola to Advisory Committee for QBM-001 (PR Newswire)
08.01.19	Q BioMed Inc Provides Shareholder Update (PR Newswire)
12.12.18	Q BioMed Announces Strategic Partnership With SRI International for Formulation and Preclinical Development of QBM-001 for Pediatric Nonverbal Disorder in Autistic Children (PR Newswire)
28.11.18	Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare (PR Newswire)
26.10.18	Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference (PR Newswire)
09.10.18	Q BioMed Provides Important Update on QBM001 Developmental Drug Targeting a Non-Verbal and Minimally Verbal Patient Subset on the Autism Spectrum (PR Newswire)
24.09.18	Q Biomed Inc. Announces Entry Into Definitive Funding Agreement for $4,000,000 (PR Newswire)
17.09.18	Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board (PR Newswire)
25.07.18	Q Biomed Inc. Extends its Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma and Initiates a Clinical Study (PR Newswire)
19.09.17	Q BioMed Announces Development Partnership With Sphaera Pharma (PR Newswire)
02.08.17	Q BioMed Inc. Closes $3,050,390 Equity Financing (PR Newswire)
10.07.17	Q BioMed Inc. to be Featured on CEO Clips Airing on Bloomberg Television (PR Newswire)
26.06.17	Q BioMed Inc. Adds Nuclear Medicine Industry Veteran to Commercialization Team (PR Newswire)
15.06.17	Q BioMed Inc. Finalizes License Agreement With Oklahoma Medical Research Foundation and the Rajiv Gandhi Centre for Biotechnology for Novel Liver Cancer Treatment (PR Newswire)
14.06.17	Q BioMed Inc. to Present at the Sixth Annual Marcum Microcap Conference in New York (PR Newswire)
09.06.17	Q BioMed Announces Attendance at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting (PR Newswire)
07.06.17	Q BioMed Inc Announces Commercialization of Non-Narcotic Metastatic Cancer Pain Drug (PR Newswire)
25.04.17	Q Biomed Announces Licensing Agreement for Development of Drug to Treat Rare Pediatric Disorder (PR Newswire)
07.02.17	Q Biomed Joins with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology to Develop Liver Cancer Chemotherapeutic (PR Newswire)
02.02.17	Q BioMed Inc. Announces Mannin Research Accepted Into Johnson & Johnson Innovation, JLABS @ Toronto (PR Newswire)
05.01.17	Q BioMed Inc. to Present at Biotech Showcase 2017 in San Francisco Jan 9 - 11th (PR Newswire)
30.11.16	Q BioMed Inc. Announces Entry Into Definitive Funding Agreement for up to $4,000,000 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	53.56	3.72 %	K V
Sonova Hldg	318.50	3.11 %	K V
Part Grp Hldg	1’381.00	2.30 %	K V
Alcon	80.90	1.81 %	K V
Lonza Grp	580.40	1.79 %	K V
Nestle	74.18	-0.75 %	K V
Geberit	500.80	-0.91 %	K V
Kuehne+Nagel Int	204.60	-1.06 %	K V
Swisscom	506.50	-1.65 %	K V
Logitech Intl	79.90	-1.75 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Q BioMed Inc

Aktien Top/Flop

Meistgelesene Nachrichten